• 1
    Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 2506.
  • 2
    Bjarnason I, Macpherson A, Mackintosh C, Buxton Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 22833.
  • 3
    Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporosis Int 1995; 5: 15660.
  • 4
    Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 716.
  • 5
    Von Tirpitz C, Pischulti G, Klaus J, et al. Osteoporosis in patients with inflammatory bowel disease — prevalence and risk factors. Z Gastroenterol 1999; 37: 512.
  • 6
    Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 17681.
  • 7
    Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 7959.
  • 8
    Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112: 17103.
  • 9
    Klaus J, Brueckel J, Steinkamp M, et al. High prevalence of vertebral fractures in patients with Crohn's disease evaluated by quantitative morphometry. Gut 2002; 51: 6548.
  • 10
    Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83: 8016.
  • 11
    Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 212.
  • 12
    Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25: 2559.
  • 13
    Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119: 90920.
  • 14
    Le-Pen C, Maurel F, Breart G, et al. The long-term effectiveness of preventive strategies for osteoporosis in postmenopausal women: a modeling approach. Osteoporosis Int 2000; 11: 52432.
  • 15
    Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 143743.
  • 16
    Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticoid-induced osteoporosis. N Engl J Med 1997; 337: 3827.
  • 17
    Pak CY, Sakhaee K, Adams Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123: 4018.
  • 18
    Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 8029.
  • 19
    Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001; 161: 232533.
  • 20
    Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 60914.
  • 21
    Von Tirpitz C, Klaus K, Brückel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 11: 1924.
  • 22
    Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 63946.
  • 23
    Felsenberg D, Wieland E, Hammermeister C, Armbrecht G, Gowin W, Raspe H. Prevalence of vertebral spinal deformities in women and men in Germany. EVOS group in Germany. Med Klin 1998; 93: 2314.
  • 24
    McCloske EV, Spector TD, Eyres KS, et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporosis Int 1993; 3: 13847.
  • 25
    Eastell R, Cedel SL, Wahner HW, et al. Classification of vertebral fractures. J Bone Miner Res 1991; 6: 20715.
  • 26
    Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001; 86: 31625.
  • 27
    Pak CY, Sakhaee K, Parcel C, et al. Fluoride bioavailability from slow-release sodium fluoride given with calcium citrate. J Bone Miner Res 1990; 5: 85762.
  • 28
    Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298307.
  • 29
    Motley RJ, Crawley EO, Evans C, Rhodes J, Comston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988; 29: 13326.
  • 30
    Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 51827.
  • 31
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 44705.
  • 32
    Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum 2002; 46: 174453.
  • 33
    Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347: 17584.
  • 34
    Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 230610.
  • 35
    Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin. Clinical relevance and potential applications. Eur J Endocrinol 2001; 145: 6813.
  • 36
    Kleerekoper M, Mendlovic DB. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr Rev 1993; 14: 31223.